Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective

American Heart Journal

Volumn 138, Issue 4 II, 1999, Pages

  Dyke, C M ^a  

^a Sanger Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

BLEEDING; CONFERENCE PAPER; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION;

EID: 0032887498     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1999.v138.a100460     Document Type: Conference Paper

References (38)

1. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-64.
2. Mascelli MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation 1997;96:3860-6.
3. Mascelli MA, Lance ET, Damaraju L, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680-8.
4. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536-42.
5. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-7.
6. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997;99:1467-71.
7. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80(suppl 4A):11B-20B.
8. Deckelbaum LI, Sax FL, Grossman W. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIA receptor. In: Sasahara AA, Loscalzo J, editors. New therapeutic agents in thrombosis and thrombolysis. New York: Marcel Dekker; 1997. p. 355-65.
9. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
10. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
11. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
12. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
13. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
14. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
15. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
16. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
17. Bergelson BA, Fishman RF, Tommaso CL. Abrupt vessel closure: changing importance, management, and consequences. Am Heart J 1997;134:362-81.
18. Levine GN, Ali MN. The role of percutaneous revascularization in the treatment of ischemic heart disease: insights from published reports and randomized clinical trials. Chest 1997;112:805-21.
19. Boylan MJ, Lytle BW, Taylor PC, et al. Have PTCA failures requiring emergent bypass operation changed? Ann Thorac Surg 1995;59:283-6.
20. Serruys PW, de Jaegere P, Kiemeneij F, et al, for the Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
21. Fischman DL, Leon MB, Baim DS, et al, for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
22. Topol EJ, Leya F, Pinkerton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease: the CAVEAT Study Group. N Engl J Med 1993;329:221-7.
23. Litvack F, Eigler N, Margolis J, et al. Percutaneous excimer laser coronary angioplasty: results in the first consecutive 3,000 patients: the ELCA Investigators. J Am Coll Cardiol 1994;23:323-9.
24. Topaz O, Rozenbaum EA, Schumacher A, et al. Solid-state mid-infrared laser facilitated coronary angioplasty: clinical and quantitative coronary angiographic results in 112 patients. Lasers Surg Med 1996;19:260-72.
25. Altmann DB, Racz M, Battleman DS, et al. Reduction in angioplasty complications after the introduction of coronary stents: results from a consecutive series of 2242 patients. Am Heart J 1996;132:503-7.
26. Bartram U, Wahlers T, Aebert H, et al. Coronary artery bypass grafting after failed percutaneous angioplasty compared to direct coronary bypass grafting in patients with unstable angina. Thorac Cardiovasc Surg 1996;44:31-4.
27. Berger PB, Stensrud PE, Daly RC, et al. Time to reperfusion and other procedural characteristics of emergency coronary artery bypass surgery after unsuccessful coronary angioplasty. Am J Cardiol 1995;76:565-9.
28. Craver JM, Justicz AG, Weintraub WS, et al. Coronary artery bypass grafting in patients after failure of intracoronary stenting. Ann Thorac Surg 1995;60:60-5.
29. Nollert G, Amend J, Reichart B. Use of the internal mammary artery as a graft in emergency coronary artery bypass grafting after failed PTCA. Thorac Cardiovasc Surg 1995;43:142-7.
30. Buffet P, Danchin N, Villemot JP, et al. Early and long-term outcome after emergency coronary artery bypass surgery after failed coronary angioplasty. Circulation 1991;84(suppl 5):III-254-9.
31. Aguirre FV, Topol EJ, Leimberger J, et al. Incidence and clinical outcome of abrupt vessel closure among patients receiving abciximab during high-risk percutaneous coronary intervention: EPIC trial results [abstract]. J Am Coll Cardiol 1997;29:394A.
32. Boehrer JD, Kereiakes DJ, Navetta FI, et al, for the EPIC Investigators. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol 1994;74:1166-70.
33. Gammie JS, Zenati M, Kormos RL, et al. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 1998;65:465-9.
34. Alvarez JM. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab. J Thorac Cardiovasc Surg 1998;115:472-3.
35. Tcheng JE. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Am J Cardiol 1997;80(suppl 4A):21B-28B.
36. Kleiman NS. Primary and secondary safety endpoints from IMPACT II. Am J Cardiol 1997;80(suppl 4A):29B-33B.
37. Juergens CP, Yeung AC, Oesterle SN. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am J Cardiol 1997;80:74-5.
38. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998;97:211-8.